Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H27N3O3S |
| Molecular Weight | 377.501 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)N1C2=C(C=CS2)C(O)=C(C(=O)NCCCN3CCCCC3)C1=O
InChI
InChIKey=SCHKZZSVELPJKU-UHFFFAOYSA-N
InChI=1S/C19H27N3O3S/c1-13(2)22-18(25)15(16(23)14-7-12-26-19(14)22)17(24)20-8-6-11-21-9-4-3-5-10-21/h7,12-13,23H,3-6,8-11H2,1-2H3,(H,20,24)
PRX-03140 is a partial agonist of the 5-HT4 receptor that is being developed by EPIX Pharmaceuticals for Alzheimer's disease. In vitro shows potent binding to 5-HT4 receptor and increased cAMP production in human embryonic kidney-293 cells expressing recombinant rat 5-HT(4) receptors. In the clinical trial, PRX-03140 was associated with a statistically significant improvement in the Alzheimer’s Disease Assessment Scale.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
869493-21-0
Created by
admin on Sat Dec 16 05:49:06 GMT 2023 , Edited by admin on Sat Dec 16 05:49:06 GMT 2023
|
PRIMARY | |||
|
54677674
Created by
admin on Sat Dec 16 05:49:06 GMT 2023 , Edited by admin on Sat Dec 16 05:49:06 GMT 2023
|
PRIMARY | |||
|
PRX-03140
Created by
admin on Sat Dec 16 05:49:06 GMT 2023 , Edited by admin on Sat Dec 16 05:49:06 GMT 2023
|
PRIMARY | |||
|
DB05596
Created by
admin on Sat Dec 16 05:49:06 GMT 2023 , Edited by admin on Sat Dec 16 05:49:06 GMT 2023
|
PRIMARY | |||
|
7QGN8QXG7I
Created by
admin on Sat Dec 16 05:49:06 GMT 2023 , Edited by admin on Sat Dec 16 05:49:06 GMT 2023
|
PRIMARY | |||
|
DTXSID90236013
Created by
admin on Sat Dec 16 05:49:06 GMT 2023 , Edited by admin on Sat Dec 16 05:49:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
